Glimepiride Aurobindo

Glimepiride Aurobindo is an oral tablet that contains the sulfonylurea agent glimepiride as its active ingredient. It is marketed in the European Union and is prescribed for the management of blood glucose in adults with type 2 diabetes mellitus. The medication works by stimulating insulin release from pancreatic beta cells, helping to lower elevated blood sugar levels. It is available by prescription and should be taken as directed by a clinician.

Glimepiride Aurobindo is indicated for the oral treatment of type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve glycemic control.

- Adjunct to lifestyle modifications in adults with type 2 diabetes. - Used when monotherapy with metformin does not achieve target HbA1c. - Can be combined with other oral antidiabetic agents such as DPP‑4 inhibitors. - May be prescribed for patients with stable renal function and no history of severe hypoglycemia. - Intended for chronic management, not for acute hyperglycemic crises.

The safety profile of Glimepiride Aurobindo includes both frequently observed reactions and less common but potentially serious events.

Common: - Mild to moderate hypoglycemia, especially after missed meals. - Weight gain due to increased insulin activity. - Nausea or abdominal discomfort. - Headache. - Dizziness or light‑headedness.

Serious: - Severe hypoglycemia requiring assistance. - Allergic reactions such as rash, pruritus, or angioedema. - Elevated liver enzymes indicating hepatic stress. - Blood dyscrasias including neutropenia or thrombocytopenia.

Before initiating Glimepiride Aurobindo, clinicians should evaluate several clinical factors to minimize risk.

- Assess renal and hepatic function; dose may need adjustment in impairment. - Avoid use in patients with known sulfonylurea hypersensitivity. - Caution in elderly patients due to increased hypoglycemia risk. - Monitor blood glucose regularly, especially when initiating or changing dose. - Educate patients about signs of hypoglycemia and appropriate management. - Pregnancy and lactation status should be reviewed; safety data are limited.

Glimepiride Aurobindo can interact with other medicines, affecting blood glucose levels or drug metabolism.

Avoid: - Concurrent use with other sulfonylureas or insulin may cause severe hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) can increase glimepiride concentrations. - Beta‑blockers may mask hypoglycemia symptoms.

Use with caution: - Combination with thiazolidinediones may enhance hypoglycemic effect. - Concurrent use of diuretics may affect potassium balance, influencing glucose control. - Alcohol intake can potentiate hypoglycemia, especially with large amounts.